Introduction

Demonstrating clinical equivalence under the EU Medical Device Regulation can look simple at first glance. Many manufacturers assume that if another device already exists on the market with a similar intended purpose, they can rely on that device to support their own clinical evaluation. In practice, it is much more demanding.

Under the EU MDR (Regulation (EU) 2017/745), clinical equivalence is not just a broad claim of similarity. It must be systematically demonstrated and properly justified across technical, biological, and clinical characteristics. If this justification is weak, the clinical evaluation may contain major evidence gaps, and manufacturers may be required to generate additional clinical data.

This article explains what clinical equivalence means under MDR, what is required to demonstrate it, and the common mistakes manufacturers should avoid.

What Clinical Equivalence Means Under MDR

Clinical equivalence allows a manufacturer to use clinical data from another device to support the clinical evaluation of their own device. However, this is only acceptable when the manufacturer can show that the two devices are sufficiently similar in ways that matter for safety and performance.

Under MDR, equivalence must be demonstrated across three key areas:

• Technical characteristics
• Biological characteristics
• Clinical characteristics

All three areas must be addressed. It is not enough to show that the devices have the same intended use or belong to the same product family. The comparison must be detailed, evidence-based, and scientifically justified.

Technical Characteristics

The technical comparison focuses on whether the subject device and the equivalent device are similar in design, specifications, principles of operation, and performance.

Manufacturers should assess points such as:

• Device design and configuration
• Dimensions and specifications
• Energy source or mechanism of action
• Operating principles
• Conditions of use
• Functional and performance characteristics

The goal is not necessarily to prove that the two devices are identical. Small differences may exist. What matters is whether those differences could have a clinically significant impact on safety or performance.

For example, if two devices have similar intended purposes but use different technologies to achieve the result, the manufacturer must explain why that technological difference does not affect clinical outcomes. A technical comparison that only lists similarities without discussing meaningful differences is usually not strong enough.

Biological Characteristics

The biological comparison looks at whether the devices interact with the body in a similar way.

This assessment should consider:

• Materials and substances used
• Type and duration of body contact
• Nature of tissue interaction
• Potential release of substances
• Biocompatibility-related risks

This area is especially important when the device contains materials that contact skin, mucosa, tissue, or blood. Even if two devices are similar in function, material differences may create different biological risks.

For example, a change in material composition, additives, coatings, or manufacturing residues may influence irritation, sensitization, toxicity, or other biological endpoints. Because of this, biological equivalence should never be assumed lightly. Manufacturers must provide a reasoned scientific basis showing that any material differences do not alter the clinical safety profile.

Clinical Characteristics

The clinical comparison is often the most visible part of equivalence, but it must be built on the technical and biological foundations already discussed.

Manufacturers should compare:

• Intended purpose
• Indications
• Target population
• Anatomical site of use
• Disease or condition severity
• User profile
• Clinical performance outcomes
• Safety outcomes

The clinical context of the two devices must be genuinely similar. If the subject device is intended for a different patient group, different lesion type, different anatomical location, or different severity of condition, then clinical equivalence may be difficult to justify.

This is where many weak equivalence claims fail. A manufacturer may identify a device with a similar general purpose, but the actual clinical setting is too different for the data to be transferable.

Why MDR Made Equivalence More Difficult

Under MDR, demonstrating clinical equivalence is more demanding than it was under older frameworks. The expectation is no longer limited to a general literature-based comparison. Manufacturers are expected to provide robust evidence and, in many cases, sufficient access to the data relating to the equivalent device.

That creates a practical challenge. If the equivalent device belongs to another manufacturer, access to detailed design, material, and clinical data may be limited. Without enough supporting information, it becomes difficult to justify equivalence in a way that is fully defensible.

This is one of the biggest reasons why manufacturers should assess equivalence early in the regulatory strategy. If adequate access to equivalent device data is not realistic, relying heavily on equivalence may create delays later in the clinical evaluation process.

What Strengthens an Equivalence Demonstration

A strong equivalence justification is built on structure, evidence, and traceability.

Useful elements include:

• A clear side-by-side comparison table
• Detailed assessment of technical characteristics
• Material and biological safety comparison
• Clinical data mapping between devices
• Risk-based justification for any identified differences
• Clear rationale for transferability of clinical outcomes

The comparison should not only describe similarities. It should also openly identify differences and explain why those differences do not change the safety, performance, or benefit-risk profile of the subject device.

This is where a risk-based mindset becomes essential. If a difference exists, the question is not just “Is it different?” but “Does this difference matter clinically or biologically?” A well-written equivalence section answers that clearly.

Common Mistakes Manufacturers Make

Several recurring mistakes weaken clinical equivalence claims under MDR.

One common problem is focusing only on intended use. Two devices may both be used for the same general purpose, but that does not automatically make them equivalent. Design, materials, and clinical application still need to be compared in depth.

Another issue is ignoring biological differences. Material changes are sometimes treated as minor, even when they may affect tissue response or biocompatibility risks.

A third mistake is using vague literature support. General articles about a device category are not enough. The evidence must be relevant to the specific device characteristics and clinical application being claimed.

Manufacturers also often identify differences without adequately justifying them. Listing a difference is not the same as explaining why it is not clinically significant.

Finally, some manufacturers rely on equivalence without having enough access to supporting data on the equivalent device. This creates a weak foundation that may not stand up to scrutiny.

When Equivalence May Not Be Enough

There are situations where equivalence is simply not strong enough to close the evidence gap. This may happen when:

• The technology is novel
• Material differences are significant
• The intended use has changed
• The patient population is different
• Access to equivalent device data is limited
• Clinical outcomes are not clearly transferable

In these cases, additional clinical evidence may be required. That does not always mean a large pre-market clinical investigation, but it does mean the manufacturer should not rely on equivalence alone.

Final Thoughts

Demonstrating clinical equivalence under MDR requires much more than showing that two devices look similar on paper. It is a detailed scientific and regulatory exercise that must address technical, biological, and clinical characteristics in a clear and defensible way.

A strong equivalence strategy can support a robust clinical evaluation and reduce unnecessary evidence gaps. A weak one can lead to major regulatory challenges, questions from reviewers, and the need for additional clinical data.

The key is to assess equivalence early, document it thoroughly, and justify every conclusion with evidence. Under MDR, clinical equivalence is not just about similarity. It is about proving that the available data is truly applicable to your device and sufficient to support its safety and performance.